SEC Form 4 · accession 0001479290-18-000050
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
L Daniel Browne
Officer — CEO and President · Director
Period of report
Mar 15, 2018
Accepted (ET)
Mar 16, 2018 · 8:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 15, 2018 | S | 1,000 | $32.80 | D | 130,208 | D | |
| Common StockF2 | Mar 15, 2018 | F | 2,881 | $31.65 | D | 127,327 | D | |
| Common Stock | Mar 16, 2018 | M | 20,000 | $2.55 | A | 147,327 | D | |
| Common StockF3 | Mar 16, 2018 | S | 5,452 | $31.4284 | D | 141,875 | D | |
| Common StockF4 | holding | — | — | — | 409 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common StockF5 | $2.55 | Mar 16, 2018 | M | 20,000 | A | — | Apr 29, 2018 | Common Stock | 20,000 | 0 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Browne.
- F2Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2018, to satisfy tax withholding obligations that arose in connection with the vesting of a 2016 Restricted Stock Award ("RSA") for 25,000 shares. The RSA vests in three equal annual installments from March 15, 2016, subject to Mr. Browne's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.
- F3The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.10 to $31.975. Mr. Browne undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust.
- F5The Option is fully vested as of April 28, 2012.